Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas

NCT01844583 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01844583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01844583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 25, 2013
Completion date
September 6, 2016
Enrollment
55 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, solid tumors